Last reviewed · How we verify

NCT05367466

Risk Factors of Neonatal Thrombosis

Completed Last updated 10 May 2022
What this trial tests

trial in Thrombosis in 11 participants. Completed in 10 April 2022.

Timeline
1 January 2014
Primary endpoint
30 December 2019
10 April 2022

Quick facts

Lead sponsorKırıkkale University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment11
Start date1 January 2014
Primary completion30 December 2019
Estimated completion10 April 2022

Conditions studied

Sponsor

Kırıkkale University

Who can join

1 Day and older, any sex, with Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The incidence of symptomatic thrombosis is between 2.4 and 6.8 per 1000 neonatal intensive care unit admission while it is 5.1 per 100 000 live births. Compared to adults, the anticoagulant and fibrinolytic system of newborns is significantly different. In this study, the aim is to evaluate infants with neonatal thrombosis in our unit to characterize acquired and genetic risk factors, the laboratory work-up parameters and the diagnosis approach.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Evaluation of Patients with Neonatal Thrombosis.
    Guzoglu N, Albayrak M, Aliefendioglu D. · · 2023 · cited 1× · PMID 36859514 · DOI 10.1007/s12098-023-04497-w

Verify or expand the search:

Other recruiting trials for Thrombosis

Currently open trials in the same condition.

Other Kırıkkale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05367466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing